The Alliance’s personalized treatment program
World-class care for anyone
The Alliance and Perthera have partnered to provide personalized treatment options to patients with colorectal cancer.
The Personalized Treatment Program (PTP) gives stage III and IV patients access to personalized treatment found at top cancer centers, no matter where they live. Using the power of artificial intelligence and data analysis, the program can improve treatment and save lives.
How does it work?
The Alliance’s Personalized Treatment Program provides no-cost* testing and analysis of your specific cancer and past medical history. The results provide you and your care team with personalized treatment recommendations.
- You will receive a report that suggests treatment options matched to you, your molecular profile, treatment history, and have been shown to improve patient outcomes.
- If you recently had molecular/biomarker testing, your results will be analyzed with no additional testing required.
- If you have not had testing in the last two years, Perthera will help you get tested and create a personalized report at no cost to you.*
- Perthera will follow-up with you to see how the suggestions improved your treatment. This information will be used for research to advance cancer care.
Call the Alliance’s Helpline at (877) 422-2030 to enroll or complete this form.
Program benefits
- A report will be sent directly to you and your doctor with in-depth treatment options and clinical trials, ranked by their potential to improve your treatment.
- Your report will be reviewed by Perthera’s Molecular Tumor Board, made up of cancer experts from world-renowned institutions. Having a strong understanding of personalized treatment options save you from unnecessary treatments.
- Enrolling is simple with a one-page form that takes five minutes to complete.
- The Alliance coordinates the entire process and offers support along the way.
Who is Perthera?
Perthera is a leading precision oncology company that uses powerful artificial intelligence (AI) to generate treatment recommendations for cancer patients. The Perthera Report is the only report that provides precisely-ranked treatment recommendations to help guide medical decision-making and improve survival rates.
The Perthera platform has been used by over 250 cancer centers and 10% of oncologists throughout the U.S. It has been shown to improve outcomes in certain cancer types. Perthera follows the patient’s progress and records that valuable information to enhance their own artificial intelligence (AI) and deliver it to the scientific community. The data is used to advance cancer care for patients now and into the future. With a five minute call, Perthera has everything they need to advance your cancer care to a best-in-class level.
Contact us to learn more
Call the Alliance Helpline at (877) 422-2030 or complete this form to see if the Alliance’s Personalized Treatment Program is right for you.
Top resources
Krazati approved for previously treated KRASG12C colorectal cancer
The treatment option is for patients with KRASG12C-mutated locally advanced or metastatic colorectal cancer (CRC) who have received prior treatment with fluoropyrimidine-, oxaliplatin-, and irinotecan-based chemotherapy.
Top five things to know about choosing sedation for your colonoscopy
You have a choice when it comes to colonoscopy sedation, and we’re here to help make that decision easier.
Christy Williams: Biomarker testing leads to successful treatment
Statistics suggested that Christy’s odds of survival were grim, so she leaned into her faith and kept a positive outlook. She tried to control what she could. And, critically, she received biomarker testing.